Literature DB >> 10547288

SH3 domains with high affinity and engineered ligand specificities targeted to HIV-1 Nef.

M Hiipakka1, K Poikonen, K Saksela.   

Abstract

The avid binding of HIV-1 Nef to the Src homology-3 (SH3) domain of Hck (KD 250 nM) has been shown to involve an interaction between the RT-loop of Hck-SH3 and residues in Nef outside of its prototypic polyproline type II (PPII) helix-containing SH3-ligand region. Such distinctive interactions are thought to provide specificity and affinity for other SH3/ligand protein complexes as well. Here, we have constructed and successfully displayed on the surface of M13 bacteriophage particles a complex library of SH3 domains, which are derived from Hck but carry a random hexapeptide substitution in their RT-loops (termed RRT-SH3). Using this strategy we have identified individual RRT-SH3 domains that can bind to Nef up to 40-fold more avidly than Hck-SH3. Some of these high-affinity RRT-SH3 domains resembled Hck-SH3 in that they bound much less well to a Nef variant containing an engineered F90R mutation that interferes with docking of the native Hck RT-loop. In addition, we could also select RRT-SH3 domains with an opposite specificity, which were dependent on the Arg90 residue for strong binding, and bound 100-fold less well to unmodified Nef. These results demonstrate the utility of phage-display in engineering of signaling protein interaction domains, and emphasize the importance of the RT-loop in SH3 ligand selection, thus suggesting a general strategy for creating SH3 domains with desired binding properties. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10547288     DOI: 10.1006/jmbi.1999.3225

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  18 in total

1.  Single-domain antibody-SH3 fusions for efficient neutralization of HIV-1 Nef functions.

Authors:  Jérôme Bouchet; Cécile Hérate; Carolin A Guenzel; Christel Vérollet; Annika Järviluoma; Julie Mazzolini; Salomeh Rafie; Patrick Chames; Daniel Baty; Kalle Saksela; Florence Niedergang; Isabelle Maridonneau-Parini; Serge Benichou
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

2.  Identification of preferred protein interactions by phage-display of the human Src homology-3 proteome.

Authors:  Satu Kärkkäinen; Marita Hiipakka; Jing-Huan Wang; Iivari Kleino; Marika Vähä-Jaakkola; G Herma Renkema; Michael Liss; Ralf Wagner; Kalle Saksela
Journal:  EMBO Rep       Date:  2006-02       Impact factor: 8.807

3.  Engineered SH2 domains with tailored specificities and enhanced affinities for phosphoproteome analysis.

Authors:  Gianluca Veggiani; Haiming Huang; Bradley P Yates; Jiefei Tong; Tomonori Kaneko; Rakesh Joshi; Shawn S C Li; Michael F Moran; Gerald Gish; Sachdev S Sidhu
Journal:  Protein Sci       Date:  2018-12-24       Impact factor: 6.725

Review 4.  Structure, function, and inhibitor targeting of HIV-1 Nef-effector kinase complexes.

Authors:  Ryan P Staudt; John J Alvarado; Lori A Emert-Sedlak; Haibin Shi; Sherry T Shu; Thomas E Wales; John R Engen; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2020-08-29       Impact factor: 5.157

Review 5.  NextGen protein design.

Authors:  Nicholas Sawyer; Elizabeth B Speltz; Lynne Regan
Journal:  Biochem Soc Trans       Date:  2013-10       Impact factor: 5.407

6.  MC159 of Molluscum Contagiosum Virus Suppresses Autophagy by Recruiting Cellular SH3BP4 via an SH3 Domain-Mediated Interaction.

Authors:  Constanze Schmotz; Hasan Uğurlu; Silja Vilen; Subhash Shrestha; Riku Fagerlund; Kalle Saksela
Journal:  J Virol       Date:  2019-05-01       Impact factor: 5.103

Review 7.  SH3 domains come of age.

Authors:  Brian K Kay
Journal:  FEBS Lett       Date:  2012-06-05       Impact factor: 4.124

8.  Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways.

Authors:  John Cijiang He; Mohammad Husain; Masaaki Sunamoto; Vivette D D'Agati; Mary E Klotman; Ravi Iyengar; Paul E Klotman
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

9.  Molecular design, functional characterization and structural basis of a protein inhibitor against the HIV-1 pathogenicity factor Nef.

Authors:  Sebastian Breuer; Simone I Schievink; Antje Schulte; Wulf Blankenfeldt; Oliver T Fackler; Matthias Geyer
Journal:  PLoS One       Date:  2011-05-20       Impact factor: 3.240

10.  High-affinity target binding engineered via fusion of a single-domain antibody fragment with a ligand-tailored SH3 domain.

Authors:  Annika Järviluoma; Tomas Strandin; Sebastian Lülf; Jérôme Bouchet; Anna R Mäkelä; Matthias Geyer; Serge Benichou; Kalle Saksela
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.